Abstract
Impact of multidisciplinary discussion on therapeutic decision in cancer patients: a prospective observational study
Journal of clinical oncology, Vol.35(15_suppl), pp.e18243-e18243
05/20/2017
DOI: 10.1200/JCO.2017.35.15_suppl.e18243
Abstract
Abstract only e18243 Background: Continued and rapid evolution of diagnosis and staging methods along with the development of new treatments has changed decision-making process of cancer patient into a more complex task. We evaluated the impact of multidisciplinary tumor board meetings (MTM) in the final decision of cancer patients approach in comparison to the initial decision based on clinical oncologist’s individual choice. Methods: Between April 2016 and January 2017, data were collected prospectively during the MTM held daily at the Antônio Ermírio de Moraes Cancer Center, Sao Paulo, Brazil. Data were gathered by filling out a questionnaire. The therapeutic plan initialy proposed by the physician was compared to the proposal offered by the multidisciplinary team. We evaluated data from breast, gastrointestinal (GI) and lung cancer MTM. Results: We evaluated 100 questionnaires: 39% GI tumors, 34% lung cancer, 27% breast cancer. The main theme for discussion was selection of systemic therapy (65%). The rate of change in therapy choice was 24.6%. The recommendation suggested by the MTM surgeons and radio-oncologists showed disagreement with the one initially proposed in 21 cases. The majority of discordant cases was related to the choice of therapeutic method (57%) with 42% changes in the chemotherapy protocol. Eight patients were submitted to genetic test and mutations search. Only two cases were recommended for clinical trial enrollment. Conclusions: The rate of therapy plan change after MTM is in accordance with international studies. The largest volume of discussions on systemic therapies reflects the large number of new therapies as well as new treatment strategies. This research highlights the potential of multidisciplinary discussions in changing decision-making in cancer cases, allowing a more comprehensive care with the patient. In addition, a MTM allows the access of more patients to new medications made available through clinical trials and protocols. The small number of patients referred to a clinical study reflects the lack of clinical protocols available in Brazil, a problem that needs to be acknowledged and become a priority for Brazilian medical societies and regulatory agencies.
Details
- Title: Subtitle
- Impact of multidisciplinary discussion on therapeutic decision in cancer patients: a prospective observational study
- Creators
- Carla Pires Amaro - Antonio Ermirio de Moraes Oncology Center, São Paulo, BrazilLarissa Gomes - Antonio Ermirio de Moraes Oncology Center, São Paulo, BrazilDaniel Almeida - Antonio Ermirio de Moraes Oncology Center, São Paulo, BrazilKelly Reiner - Antonio Ermirio de Moraes Oncology Center, São Paulo, BrazilGustavo Fernandes Godoy AlmeidaMarcelo Rocha S Cruz - Antonio Ermirio de Moraes Oncology Center, São Paulo, Brazil
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.35(15_suppl), pp.e18243-e18243
- DOI
- 10.1200/JCO.2017.35.15_suppl.e18243
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Language
- English
- Date published
- 05/20/2017
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985150647102771
Metrics
1 Record Views